U.S. markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.38%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.83%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.07%)
     
  • BTC-USD

    35,825.46
    -1,945.59 (-5.15%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     

Aldeyra Seeks To Raise $125M Via Equity To Support Reproxalap US Application

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Aldeyra Therapeutics Inc (NASDAQ: ALDX) intends to sell 5 million shares of its common stock in an underwritten public offering.

  • Underwriters will have an option to purchase up to an additional $18.75 million of shares.

  • Aldeyra intends to use the net proceeds to prepare a potential marketing application submission of its lead compound, reproxalap, the preparations for its commercial launch, if approved, pipeline development programs, and working capital purposes.

  • Jefferies and SVB Leerink are acting as joint book-running managers for the offering.

  • Yesterday, the company announced positive top-line results from the Phase 3 trial evaluating 0.25% reproxalap in allergic conjunctivitis, sending shares to climb more than 30%.

  • Data showed that Reproxalap easily achieved the primary endpoint of the study (reduction in eye itching) and secondary endpoints with a high level of statistical significance.

  • Aldeyra's next step is to meet with the FDA about a path to approval for reproxalap. This meeting is expected to take place in the second half of this year, with a potential regulatory filing for approval on the way afterward.

  • The company had cash and equivalents of $138.4 million as of March 31, 2021.

  • Price Action: ALDX shares are down 5.4% at $14.05 in the premarket on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.